Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).

被引：4
|
作者：
Chari, Ajai
Richter, Joshua Ryan
Shah, Nina
Wong, Sandy Wai Kuan
Jagannath, Sundar
Cho, Hearn J.
Biran, Noa
Wolf, Jeffrey
Parekh, Samir S.
Munster, Pamela N.
Madduri, Deepu
Campana, Frank
Martin, Thomas G.
机构：
[1] Mt Sinai, Icahn Sch Med, Tisch Canc Inst, New York, NY USA
[2] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Tufts, San Francisco, CA USA
[5] Mt Sinai Hosp, New York, NY 10029 USA
[6] Mt Sinai, Hematol & Med Oncol, Icahn Sch Med, New York, NY USA
[7] UCSF Med Ctr, San Francisco, CA USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
[10] Mt Sinai Med Ctr, New York, NY 10029 USA
[11] Sanofi US, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8014
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
    Kaufman, Jonathan L.
    Mina, Roberto
    Jakubowiak, Andrzej J.
    Zimmermann, Todd L.
    Wolf, Jeffrey J.
    Lewis, Colleen
    Gleason, Charise
    Sharp, Cathy
    Martin, Thomas
    Heffner, Leonard T.
    Nooka, Ajay K.
    Harvey, R. Donald
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2019, 9 (1)
  • [42] A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Richter, Joshua Ryan
    McNeill, Ann
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    McBride, Laura
    Raucci, Laura
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Smith, Judith
    Mato, Anthony R.
    Bilotti, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study
    Usmani, Saad
    Karanes, Chatchada
    Bensinger, William I.
    D'Souza, Anita
    Raje, Noopur
    Tuchman, Sascha
    Sborov, Douglas
    Kanagavel, Dheepak
    Dubin, Franck
    Campana, Frank
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E283 - E283
  • [44] Isatuximab Updates for Nurses: Isatuximab (Isa) Plus Carfilzomib (K) and Dexamethasone (d) Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients (IKEMA)
    Wilmoth, Jenai
    Marion, Sylvia
    Kellam, Christine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S420 - S421
  • [45] Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
    Mingyuan Sun
    Hongmei Jing
    Xiaoyan Qu
    Fei Dong
    Yi Li
    Zhaoyi Feng
    Samira Ziti-Ljajic
    Dorothee Semiond
    Lingyu Li
    Junyuan Qi
    Lugui Qiu
    Scientific Reports, 14 (1)
  • [46] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [47] Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Olsem, Jasper
    Crumpton, Brandon
    Morphey, Ashley
    Berkova, Zuzana
    Feng, Lei
    Orlowski, Robert Z.
    HAEMATOLOGICA, 2020, 105 (05) : E242 - E245
  • [48] Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM).
    AlRawashdh, Neda
    Choi, Briana
    Obeng-Kusi, Mavis
    Calamia, Matthias
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Harvey, R. Donald
    Chen, Yaozhu J.
    Lethen, Jan
    Mahue, Maya
    BLOOD, 2015, 126 (23)
  • [50] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
12345